Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6553147 | 1.00 | SIGMAR1 (0.40) | SIGMAR1ALOX15HSD17B10AKR1C3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL9424098 | 0.99 | SIGMAR1 (0.39) | SIGMAR1ALOX15HSD17B10AKR1C3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL9424101 | 0.99 | SIGMAR1 (0.39) | SIGMAR1ALOX15HSD17B10AKR1C3L3MBTL1 | |
| Fumaric Acid SCHEMBL2908209 | 0.90 | POLB (0.40) | AKR1C3L3MBTL1POLBMAPTALDH1A1 | |
| Fumaric Acid SCHEMBL4968361 | 0.90 | POLB (0.40) | AKR1C3L3MBTL1POLBMAPTALDH1A1 | |
| Fumaric Acid SCHEMBL2908206 | 0.90 | POLB (0.40) | AKR1C3L3MBTL1POLBMAPTALDH1A1 | |
| SCHEMBL9059574 | 0.87 | NPC1 (0.44) | SIGMAR1L3MBTL1POLBMAPTMEN1 | |
| SCHEMBL9059572 | 0.87 | NPC1 (0.44) | SIGMAR1L3MBTL1POLBMAPTMEN1 | |
| SCHEMBL9424227 | 0.87 | SMN1; SMN2 (0.39) | SIGMAR1ALOX15HSD17B10AKR1C3L3MBTL1 | |
| SCHEMBL9424226 | 0.87 | SMN1; SMN2 (0.39) | SIGMAR1ALOX15HSD17B10AKR1C3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946181-B1 | USE OF 2-(2-MORPHOLINOPHENYL) GUANIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES COMPLICATIONS | KNOLL GMBH (DE) | 2004-02-25 | — | — | EP | claimed |
| US-6133267-A | Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications | KNOLL AKTIENGESELLSCHAFT (DE) | 2000-10-17 | — | — | US | claimed |
| EP-0946181-A1 | USE OF 2-(2-MORPHOLINOPHENYL) GUANIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES COMPLICATIONS | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-10-06 | — | — | EP | claimed |
| EP-0927028-A1 | USE OF SIBUTRAMINE ANALOGUES TO PREVENT THE DEVELOPMENT OF DIABETES | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-07-07 | — | — | EP | claimed |
| WO-1998026782-A1 | USE OF 2-(2-MORPHOLINOPHENYL) GUANIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES COMPLICATIONS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-06-25 | — | — | WO | claimed |
| WO-1998011884-A1 | USE OF SIBUTRAMINE ANALOGUES TO PREVENT THE DEVELOPMENT OF DIABETES | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-03-26 | — | — | WO | claimed |
| US-5223498-A | Hypoglycemic agents | THE BOOTS COMPANY PLC (GB) | 1993-06-29 | — | — | US | claimed |
| EP-0385038-B1 | ORTHO-SUBSTITUTED PHENYL AMIDINE AND PHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM | The Boots Company PLC (GB) | 1993-06-02 | — | — | EP | claimed |
| EP-0385038-A1 | Ortho-substituted phenyl amidine and phenyl guanidine derivatives and antidiabetic or hypoglycaemic agents containing them | The Boots Company PLC (GB) | 1990-09-05 | — | — | EP | claimed |
| JP-2229148-A | — | — | None | — | — | JP | disclosed |
| US-10604541-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190233449-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | US | disclosed |
| EP-2850073-B1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9174965-B2 | Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| US-5373008-A | Phenylamidine and phenylguanidine derivatives and their use as anti-diabetic agents | THE BOOTS COMPANT PLC. (GB) | 1994-12-13 | — | — | US | disclosed |
| US-5223498-A | Hypoglycemic agents | THE BOOTS COMPANY PLC (GB) | 1993-06-29 | — | — | US | disclosed |
| EP-0385038-B1 | ORTHO-SUBSTITUTED PHENYL AMIDINE AND PHENYL GUANIDINE DERIVATIVES AND ANTIDIABETIC OR HYPOGLYCAEMIC AGENTS CONTAINING THEM | The Boots Company PLC (GB) | 1993-06-02 | — | — | EP | disclosed |
| CN-1057648-A | Therapeutical agent | BOOTS CO PLC (GB) | 1992-01-08 | — | — | CN | disclosed |
| JP-H02229148-A | HYPOGLYCEMIC AMIDINE COMPOUND AND GUANIDINE COMPOUND | BOOTS CO PLC:THE | 1990-09-11 | — | — | JP | disclosed |
| EP-0385038-A1 | Ortho-substituted phenyl amidine and phenyl guanidine derivatives and antidiabetic or hypoglycaemic agents containing them | The Boots Company PLC (GB) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604541-B2 | Glucokinase activators and methods of using same | GCK, GCKR, GALK1 | SIGMAR1 3888/4885ALOX15 3140/4885HSD17B10 1538/4885 |
| US-20190233449-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCK, GCKR, GALK1 | SIGMAR1 3888/4885ALOX15 3140/4885HSD17B10 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.